BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

 

• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
• OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
• Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
• No drug related discontinuations to date

https://www.globenewswire.com/news-release/2024/09/11/2944400/0/en/BriaCell-Reports-Positive-Overall-Survival-OS-in-Metastatic-Breast-Cancer.html